{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Bendamustine Hydrochloride is a generic prescription drug, available as an injectable powder in 25 mg and 100 mg vials, administered intravenously. It's an alkylating agent used to treat certain blood cancers like chronic lymphocytic leukemia and non-Hodgkin lymphoma. Manufactured by Accord Healthcare, Inc. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Bendamustine hydrochloride \u2014 ANDA 208194 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208194", "mediaType": "text/html", "title": "Bendamustine hydrochloride"}], "identifier": "ANDA208194", "issued": "2016-09-16", "keyword": ["drug", "drug-manufacturers", "fda", "pharmaceuticals", "prescription-drugs"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Bendamustine hydrochloride"}